$AIM
AIM ImmunoTech Inc. Stock $aim

$aim Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000094664415000048 Filed on August 12, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$23.00K	$47.00K	$36.00K
YoY Change	-48.89%	30.56%	0.0%
Cost Of Revenue	$353.0K	$507.0K	$294.0K
YoY Change	15.36%	72.45%	-53.7%
Gross Profit	-$330.0K	-$460.0K	-$258.0K
YoY Change	26.44%	78.29%	-56.93%
Gross Profit Margin	-1434.78%	-978.72%	-716.67%
Selling, General & Admin	$1.690M	$2.000M	$2.500M
YoY Change	-22.12%	-20.0%	37.36%
% of Gross Profit
Research & Development	$1.968M	$2.439M	$2.330M
YoY Change	3.91%	4.68%	0.52%
% of Gross Profit
Depreciation & Amortization	$290.0K	$290.0K	$270.0K
YoY Change	-3.33%	7.41%	3.85%
% of Gross Profit
Operating Expenses	$1.968M	$2.439M	$2.330M
YoY Change	3.91%	4.68%	0.52%
Operating Profit	-$3.983M	-$4.901M	-$5.085M
YoY Change	-7.99%	-3.62%	7.41%
Interest Expense	$180.0K	$60.00K	$130.0K
YoY Change	38.46%	-53.85%	-62.86%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00	$0.00
YoY Change			-100.0%
Pretax Income	-$3.800M	-$4.850M	-$4.960M
YoY Change	-9.52%	-2.22%	15.89%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.803M	-$4.845M	-$4.956M
YoY Change	-9.5%	-2.24%	15.71%
Net Earnings / Revenue	-16534.78%	-10308.51%	-13766.67%
Basic Earnings Per Share
Diluted Earnings Per Share	-$8.085M	-$10.78M	-$14.17M
COMMON SHARES
Basic Shares Outstanding	246.9M shares	232.6M shares	183.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.38M	$15.71M	$20.21M
YoY Change	-28.97%	-22.27%	-37.85%
Cash & Equivalents	$1.161M	$1.842M	$2.617M
Short-Term Investments	$11.21M	$13.87M	$17.60M
Other Short-Term Assets	$280.0K	$340.0K	$250.0K
YoY Change	16.67%	36.0%	-30.56%
Inventory	$1.330M	$1.010M	$0.00
Prepaid Expenses	$278.0K	$338.0K	$246.0K
Receivables
Other Receivables
Total Short-Term Assets	$13.98M	$17.06M	$20.46M
YoY Change	-20.87%	-16.6%	-37.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.50M	$11.72M	$4.845M
YoY Change	143.87%	141.9%	-2.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$134.0K	$134.0K	$134.0K
YoY Change	0.0%	0.0%	-1.47%
Total Long-Term Assets	$12.52M	$12.81M	$13.09M
YoY Change	-3.5%	-2.18%	-1.28%
TOTAL ASSETS
Total Short-Term Assets	$13.98M	$17.06M	$20.46M
Total Long-Term Assets	$12.52M	$12.81M	$13.09M
Total Assets	$26.50M	$29.87M	$33.55M
YoY Change	-13.52%	-10.98%	-27.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.506M	$1.598M	$1.471M
YoY Change	-38.46%	8.63%	52.12%
Accrued Expenses	$1.818M	$1.497M	$2.659M
YoY Change	2.08%	-43.7%	47.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$0.00	$10.00K	$30.00K
YoY Change	-100.0%	-66.67%	-25.0%
Total Short-Term Liabilities	$3.327M	$3.102M	$4.161M
YoY Change	-21.85%	-25.45%	-57.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$10.00K
YoY Change		-100.0%	-75.0%
Other Long-Term Liabilities			$10.00K
YoY Change			-90.0%
Total Long-Term Liabilities	$0.00	$0.00	$20.00K
YoY Change	-100.0%	-100.0%	-85.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.327M	$3.102M	$4.161M
Total Long-Term Liabilities	$0.00	$0.00	$20.00K
Total Liabilities	$3.330M	$3.100M	$4.181M
YoY Change	-22.07%	-25.86%	-58.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$289.9M	-$286.1M	-$269.1M
YoY Change	6.05%	6.3%	6.8%
Common Stock	$313.4M	$313.0M	$298.4M
YoY Change	4.55%	4.89%	3.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.17M	$26.76M	$29.37M
YoY Change
Total Liabilities & Shareholders Equity	$26.50M	$29.87M	$33.55M
YoY Change	-13.52%	-10.98%	-27.29%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$3.803M	-$4.845M	-$4.956M
YoY Change	-9.5%	-2.24%	15.71%
Depreciation, Depletion And Amortization	$290.0K	$290.0K	$270.0K
YoY Change	-3.33%	7.41%	3.85%
Cash From Operating Activities	-$3.500M	-$4.980M	-$3.310M
YoY Change	-5.91%	50.45%	-12.43%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$220.0K	-$250.0K
YoY Change	-100.0%	-12.0%	-32.43%
Acquisitions
YoY Change
Other Investing Activities	$2.450M	$50.00K	$10.00K
YoY Change	96.0%	400.0%	-99.74%
Cash From Investing Activities	$2.440M	-$170.0K	-$240.0K
YoY Change	128.04%	-29.17%	-106.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	380.0K	4.040M	2.070M
YoY Change	-70.77%	95.17%	-10450.0%
NET CHANGE
Cash From Operating Activities	-3.500M	-4.980M	-3.310M
Cash From Investing Activities	2.440M	-170.0K	-240.0K
Cash From Financing Activities	380.0K	4.040M	2.070M
Net Change In Cash	-680.0K	-1.110M	-1.480M
YoY Change	-49.63%	-25.0%	410.34%
FREE CASH FLOW
Cash From Operating Activities	-$3.500M	-$4.980M	-$3.310M
Capital Expenditures	$0.00	-$220.0K	-$250.0K
Free Cash Flow	-$3.500M	-$4.760M	-$3.060M
YoY Change	-1.13%	55.56%	-10.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1009000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000946644
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	246886840	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	HEMISPHERX BIOPHARMA INC
CY2014Q4	heb	Accrued Production Cost AccruedProductionCost	0	USD
CY2015Q2	heb	Accrued Production Cost AccruedProductionCost	26000	USD
CY2014Q4	heb	Availableforsale Securities Continuous Unrealized Loss Position Numberof Securitiesin Loss Position AvailableforsaleSecuritiesContinuousUnrealizedLossPositionNumberofSecuritiesinLossPosition	2	investment
CY2015Q2	heb	Availableforsale Securities Continuous Unrealized Loss Position Numberof Securitiesin Loss Position AvailableforsaleSecuritiesContinuousUnrealizedLossPositionNumberofSecuritiesinLossPosition	2	investment
CY2015Q1	heb	Funds Received From Sale Of Income Tax Net Operating Losses FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses	1374000	USD
CY2014Q2	heb	Funds Received From Sale Of Income Tax Net Operating Losses FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses	0	USD
	heb	Funds Received From Sale Of Income Tax Net Operating Losses FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses	1126000	USD
CY2015Q2	heb	Funds Received From Sale Of Income Tax Net Operating Losses FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses	0	USD
	heb	Funds Received From Sale Of Income Tax Net Operating Losses FundsReceivedFromSaleOfIncomeTaxNetOperatingLosses	1374000	USD
	heb	Inventory Production InventoryProduction	0	USD
	heb	Inventory Production InventoryProduction	1126000	USD
	heb	Inventory Spoilage InventorySpoilage	0	USD
	heb	Inventory Spoilage InventorySpoilage	117000	USD
	heb	Issuance Of Common Stock For Accounts Payable And Accrued Expenses IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses	38000	USD
	heb	Issuance Of Common Stock For Accounts Payable And Accrued Expenses IssuanceOfCommonStockForAccountsPayableAndAccruedExpenses	672000	USD
	heb	Number Of Domestic Subsidiaries NumberOfDomesticSubsidiaries	3	subsidiary
	heb	Proceedsfrom Refundof Capital Lease Deposits ProceedsfromRefundofCapitalLeaseDeposits	2000	USD
	heb	Proceedsfrom Refundof Capital Lease Deposits ProceedsfromRefundofCapitalLeaseDeposits	0	USD
	heb	Sharebased Compensation Arrangementby Sharebased Payment Award Optionsand Warrants Grantsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandWarrantsGrantsinPeriodGross	855000	shares
	heb	Sharebased Compensation Arrangementby Sharebased Payment Award Optionsand Warrants Grantsin Period Gross SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsandWarrantsGrantsinPeriodGross	800000	shares
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2081000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1598000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2333000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1497000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	2333000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1497000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	404000	USD
CY2015Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	266000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5000000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5458000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-160000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-186000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	302729000	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	312764000	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	276000	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	79000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23730334	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-112000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17228280	shares
CY2014Q4	us-gaap	Assets Assets	29440000	USD
CY2015Q2	us-gaap	Assets Assets	29866000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	16507000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	17061000	USD
CY2014Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2015Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	13952000	USD
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	13872000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	160000	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	186000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	14112000	USD
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	14058000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	54000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	36000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	160000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	186000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	13952000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	13872000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	106000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	150000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	5928000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	5884000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	8024000	USD
CY2015Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	7988000	USD
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	13952000	USD
CY2015Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	13872000	USD
CY2014Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	0	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	22000	USD
CY2015Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	7000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	803000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2617000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2156000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1842000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1814000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-314000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	204004818	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-61000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	245483480	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	204004818	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	245483480	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	204000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	245000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4809000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8624000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4982000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-8316000	USD
CY2014Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	7337000	USD
CY2015Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	294000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	617000	USD
CY2015Q2	us-gaap	Cost Of Revenue CostOfRevenue	507000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	879000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	5121000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	10309000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	4948000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	9907000	USD
	us-gaap	Depreciation Depreciation	332000	USD
	us-gaap	Depreciation Depreciation	458000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2015Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2014Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	1806000	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	934000	USD
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	348000	USD
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	269000	USD
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1000	USD
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	861000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	951000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2497000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5036000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2002000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3915000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	238000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	189000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1431000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-836000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2014Q2	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	3000	USD
	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	6000	USD
CY2015Q2	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	0	USD
	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	2000	USD
	us-gaap	Interest Paid InterestPaid	-9000	USD
	us-gaap	Interest Paid InterestPaid	-2000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2014Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2015Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	1009000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29440000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29866000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4436000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3102000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8440000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9278000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-420000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-355000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6206000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9237000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5085000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10197000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4901000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9824000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	123000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	271000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	134000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	134000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	168000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-26000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8316000	USD
CY2014Q2	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	131000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	284000	USD
CY2015Q2	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	56000	USD
	us-gaap	Other Interest And Dividend Income OtherInterestAndDividendIncome	162000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	54000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	120000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	169000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	36000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	-54000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	266000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	240000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	399000	USD
CY2015Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	338000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8458000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9293000	USD
CY2014Q2	us-gaap	Profit Loss ProfitLoss	-4956000	USD
	us-gaap	Profit Loss ProfitLoss	-8792000	USD
CY2015Q2	us-gaap	Profit Loss ProfitLoss	-4845000	USD
	us-gaap	Profit Loss ProfitLoss	-8290000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9601000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17178000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4601000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11720000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	18000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	15000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2330000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4656000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2439000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5113000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-277769000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-286059000	USD
CY2014Q2	us-gaap	Revenues Revenues	36000	USD
	us-gaap	Revenues Revenues	112000	USD
CY2015Q2	us-gaap	Revenues Revenues	47000	USD
	us-gaap	Revenues Revenues	83000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	36000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	112000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	47000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	83000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1356
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.6974
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Black-Scholes-Merton
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0023
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0006
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	672000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9293000	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	111000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	198000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	111000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	25004000	USD
CY2015Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26764000	USD
CY2014Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	147000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	168000	USD
CY2015Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-137000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-26000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	185749722	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	181265253	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	236149999	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	224954200	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis Of Presentation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the financial statements of Hemispherx Biopharma, Inc. and its wholly-owned subsidiaries (collectively, “Hemispherx”, “Company”, “we or “us”). The Company has </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> domestic subsidiaries: BioPro Corp., BioAegean Corp. and Core Biotech Corp., all of which are incorporated in Delaware and are dormant. The Company also has a foreign subsidiary, Hemispherx Biopharma Europe N.V./S.A., which was established in Belgium in 1998. All significant intercompany balances and transactions have been eliminated in consolidation. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the opinion of Management, all adjustments necessary for a fair presentation of such consolidated financial statements have been included. Such adjustments consist of normal recurring items. Interim results are not necessarily indicative of results for a full year.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim consolidated financial statements and notes thereto are presented as permitted by the Securities and Exchange Commission (“SEC”), and do not contain certain information which will be included in the Company’s annual consolidated financial statements and notes thereto.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements for the years ended December 31, 2014 and 2013, contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.</font></div></div>

Files In Submission

Name	View Source	Status
0000946644-15-000048-index-headers.html	Edgar Link	pending
0000946644-15-000048-index.html	Edgar Link	pending
0000946644-15-000048.txt	Edgar Link	pending
0000946644-15-000048-xbrl.zip	Edgar Link	pending
emispherxemergehealth_image1.jpg	Edgar Link	pending
emispherxemergehealth_image2.jpg	Edgar Link	pending
emispherxemergehealt_image10.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
heb-20150331.xml	Edgar Link	completed
heb-20150331.xsd	Edgar Link	pending
heb-20150331_cal.xml	Edgar Link	unprocessable
heb-20150331_def.xml	Edgar Link	unprocessable
heb-20150331_lab.xml	Edgar Link	unprocessable
heb-20150331_pre.xml	Edgar Link	unprocessable
heb-2015063010q.htm	Edgar Link	pending
heb-20150630xex101armada.htm	Edgar Link	pending
heb-20150630xex102bioridge.htm	Edgar Link	pending
heb-20150630xex103mytomorr.htm	Edgar Link	pending
heb-20150630xex104emergeal.htm	Edgar Link	pending
heb-20150630xex311.htm	Edgar Link	pending
heb-20150630xex312.htm	Edgar Link	pending
heb-20150630xex321.htm	Edgar Link	pending
heb-20150630xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIM
AIM ImmunoTech Inc. Stock $aim

2015 Q3 Form 10-Q Financial Statement

#000094664415000048 Filed on August 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM AIM ImmunoTech Inc. Stock $aim

2015 Q3 Form 10-Q Financial Statement

#000094664415000048 Filed on August 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIM
AIM ImmunoTech Inc. Stock $aim